10X Genomics Valuation
| TXG Stock | USD 22.33 0.04 0.18% |
At this time, the entity appears to be overvalued. 10X Genomics shows a prevailing Real Value of $20.85 per share. The current price of the entity is $22.33. Our model approximates the value of 10X Genomics from inspecting the entity fundamentals such as profit margin of (0.07) %, and Shares Outstanding of 117.67 M as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting 10X Genomics' valuation include:
Price Book 3.7123 | Enterprise Value | Enterprise Value Ebitda 643.9343 | Price Sales 4.4954 | Forward PE 196.0784 |
Overvalued
Today
Please note that 10X Genomics' price fluctuation is not too volatile at this time. Calculation of the real value of 10X Genomics is based on 3 months time horizon. Increasing 10X Genomics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the 10X stock is determined by what a typical buyer is willing to pay for full or partial control of 10X Genomics. Since 10X Genomics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of 10X Stock. However, 10X Genomics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 22.33 | Real 20.85 | Target 20.14 | Hype 22.37 | Naive 26.12 |
The real value of 10X Stock, also known as its intrinsic value, is the underlying worth of 10X Genomics Company, which is reflected in its stock price. It is based on 10X Genomics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of 10X Genomics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of 10X Genomics helps investors to forecast how 10X stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of 10X Genomics more accurately as focusing exclusively on 10X Genomics' fundamentals will not take into account other important factors: When choosing an evaluation method for 10X Genomics, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
10X Genomics Cash |
|
10X Revenue by Product
10X Genomics Total Value Analysis
10X Genomics is at this time anticipated to have company total value of 2.52 B with market capitalization of 2.89 B, debt of 157.74 M, and cash on hands of 499.73 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the 10X Genomics fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.52 B | 2.89 B | 157.74 M | 499.73 M |
10X Genomics Investor Information
About 98.0% of the company shares are owned by institutional investors. The book value of 10X Genomics was at this time reported as 6.24. The company has Price/Earnings To Growth (PEG) ratio of 0.13. 10X Genomics recorded a loss per share of 0.35. The entity had not issued any dividends in recent years. The firm had 1:2 split on the 17th of July 2006. Based on the key indicators related to 10X Genomics' liquidity, profitability, solvency, and operating efficiency, 10X Genomics is not in a good financial situation at this time. It has a very high probability of going through financial hardship in April.10X Genomics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. 10X Genomics has an asset utilization ratio of 61.73 percent. This implies that the Company is making $0.62 for each dollar of assets. An increasing asset utilization means that 10X Genomics is more efficient with each dollar of assets it utilizes for everyday operations.10X Genomics Profitability Analysis
Based on 10X Genomics' profitability indicators, 10X Genomics may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in April. Profitability indicators assess 10X Genomics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2018-03-31 | Previous Quarter -27.5 M | Current Value -16.3 M | Quarterly Volatility 72.7 M |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.84 | 0.6905 |
|
|
For 10X Genomics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of 10X Genomics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well 10X Genomics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between 10X Genomics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of 10X Genomics over time as well as its relative position and ranking within its peers.
10X Genomics Earnings per Share Projection vs Actual
The next projected EPS of 10X Genomics is estimated to be -0.0467 with future projections ranging from a low of -0.06 to a high of -0.03. 10X Genomics' most recent 12-month trailing earnings per share (EPS TTM) is at -0.35. Please be aware that the consensus of earnings estimates for 10X Genomics is based on EPS before non-recurring items and includes expenses related to employee stock options.10X Genomics Earnings Estimation Breakdown
The calculation of 10X Genomics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of 10X Genomics is estimated to be -0.0467 with the future projection ranging from a low of -0.06 to a high of -0.03. Please be aware that this consensus of annual earnings estimates for 10X Genomics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.06 Lowest | Expected EPS | -0.03 Highest |
10X Genomics Earnings Projection Consensus
Suppose the current estimates of 10X Genomics' value are higher than the current market price of the 10X Genomics stock. In this case, investors may conclude that 10X Genomics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and 10X Genomics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 30th of June 2026 | Current EPS (TTM) | |
| 17 | 51.53% | 0.0 | -0.0467 | -0.35 |
10X Genomics Ownership Allocation
The majority of 10X Genomics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in 10X Genomics to benefit from reduced commissions. Hence, institutional investors are subject to a different set of regulations than regular investors in 10X Genomics. Please pay attention to any change in the institutional holdings of 10X Genomics as this could imply that something significant has changed or is about to change at the company.10X Genomics Profitability Analysis
The company reported the last year's revenue of 642.82 M. Reported Net Loss for the year was (43.54 M) with profit before taxes, overhead, and interest of 444.38 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates 10X Genomics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in 10X Genomics and how it compares across the competition.
About 10X Genomics Valuation
The stock valuation mechanism determines 10X Genomics' current worth on a weekly basis. Our valuation model uses a comparative analysis of 10X Genomics. We calculate exposure to 10X Genomics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of 10X Genomics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 443.9 M | 328 M | |
| Pretax Profit Margin | (0.06) | (0.07) | |
| Operating Profit Margin | (0.17) | (0.18) | |
| Net Loss | (0.07) | (0.07) | |
| Gross Profit Margin | 0.69 | 0.84 |
10X Genomics Growth Indicators
Investing in growth stocks can be very risky. If the company such as 10X Genomics does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 124.7 M | |
| Forward Price Earnings | 196.0784 |
10X Genomics Current Valuation Indicators
Valuation refers to the process of determining the present value of 10X Genomics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value 10X we look at many different elements of the entity such as 10X's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as 10X Genomics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use 10X Genomics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes 10X Genomics' worth.Complementary Tools for 10X Stock analysis
When running 10X Genomics' price analysis, check to measure 10X Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 10X Genomics is operating at the current time. Most of 10X Genomics' value examination focuses on studying past and present price action to predict the probability of 10X Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 10X Genomics' price. Additionally, you may evaluate how the addition of 10X Genomics to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |